Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. i-direct

I-DireCT SIGNED

Immune DIREcted and Cancer-selective immunoTherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 I-DireCT project word cloud

Explore the words cloud of the I-DireCT project. It provides you a very rough idea of what is the project "I-DireCT" about.

drug    scientists    network    eid    immunocytokines    qualified    multidisciplinary    off    checkpoints    commercial    tumor    oncology    carry    immune    additional    co    expanding    edge    doctorate    carefully    revolutionized    antibodies    bilateral    discoveries    disciplines    optimized    translate    array    positions    immunostimulatory    material    cancer    operations    timed    bispecific    outstanding    restricted    formulations    immunotherapeutics    biomedical    immunomodulatory    fosters    assume    18    engineering    disciplinary    career    immunology    nanotech    designed    sectoral    physical    uniquely    academic    breakthrough    central    generate    cutting    training    industry    academia    young    scientific    industrial    ranging    core    secondments    pivotal    expertise    esr    antibody    immunotherapy    bio    hereby    release    issue    ideas    optimal    innovative    stage    sciences    combines    direct    limits    appointed    generation    chemistry    science    hereto    immunotherapeutic    active    months    inter   

Project "I-DireCT" data sheet

The following table provides information about the project.

Coordinator		 ACADEMISCH ZIEKENHUIS GRONINGEN 

Organization address
address: HANZEPLEIN 1
city: GRONINGEN
postcode: 9713 GZ
website: www.umcg.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 2˙533˙358 €
 EC max contribution 2˙533˙358 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-EID
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) coordinator 929˙669.00
2    INOCURE SRO CZ (PRAHA) participant 587˙178.00
3    Surflay Nanotec GmbH DE (BERLIN) participant 505˙576.00
4    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 379˙182.00
5    KAHR MEDICAL LTD IL (JERUSALEM) participant 131˙750.00

Map

 Project objective

I-DireCT is a European Industrial Doctorate (EID) training network designed to provide training and carry out breakthrough research on the rapidly expanding and high impact field of cancer immunotherapy in a carefully integrated academic and inter-sectoral programme. Hereby, we aim to develop next-generation immunotherapeutics and deliver a set of early stage researchers uniquely qualified for a career in academia and/or industry.

Current immunomodulatory antibodies that target pivotal immune checkpoints have revolutionized the field of oncology. However, off-tumor activity limits their application. The objective of I-Direct is to address this issue by 1. developing innovative bispecific antibodies and immunocytokines with tumor-restricted immunostimulatory effects and 2. developing optimized delivery systems to ensure optimal timed release of bio-active drug. Hereto, I-DireCT combines state-of-the-art industrial design of nanotech-based drug formulations with innovative academic and industrial immunotherapeutic concepts into the next-generation of cancer immunotherapeutics.

At the core of I-DireCT is its training objective to offer a cutting-edge multidisciplinary training programme that will enable outstanding young scientists to generate breakthrough ideas and assume leading positions in academia and industry. This training programme includes an array of disciplines, ranging from biomedical sciences (e.g. immunology, antibody engineering) and physical sciences (e.g. chemistry, material science) to drug design & development.

Industrial partners are central to the programme and provide pivotal inter-sectoral expertise on how to translate scientific discoveries into commercial reality, with each ESR being appointed at an inter-sectoral partner for 18 months, as well as through additional secondments. Further, I-Direct will enable long-term multi-disciplinary research and fosters bilateral co-operations between academia and industry.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "I-DIRECT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "I-DIRECT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

TECHNOTRAIN (2018)

Enabling TECHNOlogies-driven chemistry: a tailored TRAINing research program for batch and flow synthesis of chiral amino derivatives

Read More  

MONPLAS (2020)

The training of early stage researchers for the development of technologies to monitor concentrations of micro and nanoplastics in water for their presence, uptake and threat to animal and human life.

Read More  

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More